Avalo Therapeutics $AVTX

Health Care · NASDAQ

$6.76
+0.01 (+0.15%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 26, 2026, the first target we tracked for AVTX.

Avalo Therapeutics (AVTX) is trading up at $6.76 (+0.15%) on NASDAQ, as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Analyst price targets on AVTX

One firm's current price target on Avalo Therapeutics: $16 — 137% above the current $6.76. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateOct 26, 2026 FirmOppenheimer RatingOutperform · lowers Targetat $6.93 · $16 +131% Horizonby Oct 2027 StatusOpen

Entry price $6.93, the close nearest Oct 26, 2026, when the target was reported; the target is +131% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 26, 2027.

Source Oppenheimer cuts Avalo Therapeutics price target on trial concerns Investing.com · Oct 26, 2026 · opens the publisher's site
to $16 from $35 while maintaining an Outperform rating

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Avalo Therapeutics revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$27.8M−$28.3M−$84.4MFY2016 revenue: $1.15MFY2016 net income: −$16.5M · Net margin −1428.6%'16FY2017 revenue: $27.8MFY2017 net income: $11.9M · Net margin 42.7%'17FY2018 revenue: $7.03MFY2018 net income: −$40.1M · Net margin −569.9%'18FY2019 revenue: $6.75MFY2019 net income: −$16.1M · Net margin −238.1%'19FY2020 revenue: $6.70MFY2020 net income: −$63.5M · Net margin −947.9%'20FY2021 revenue: $5.40MFY2021 net income: −$84.4M · Net margin −1563.1%'21FY2022 revenue: $18.1MFY2022 net income: −$41.7M · Net margin −230.8%'22FY2023 revenue: $1.92MFY2023 net income: −$31.5M · Net margin −1639.5%'23FY2024 revenue: $441.0KFY2024 net income: −$35.1M · Net margin −7965.8%'24FY2025 revenue: $59.0KFY2025 net income: −$78.3M · Net margin −132642.4%'25−129.5%−100%−50%0%FY2016 net margin: −1428.6% (off the scale, which stops at −129.5%)FY2017 net margin: 42.7%FY2018 net margin: −569.9% (off the scale, which stops at −129.5%)FY2019 net margin: −238.1% (off the scale, which stops at −129.5%)FY2020 net margin: −947.9% (off the scale, which stops at −129.5%)FY2021 net margin: −1563.1% (off the scale, which stops at −129.5%)FY2022 net margin: −230.8% (off the scale, which stops at −129.5%)FY2023 net margin: −1639.5% (off the scale, which stops at −129.5%)FY2024 net margin: −7965.8% (off the scale, which stops at −129.5%)FY2025 net margin: −132642.4% (off the scale, which stops at −129.5%)
Avalo Therapeutics annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$1.15M$27.8M$7.03M$6.75M$6.70M$5.40M$18.1M$1.92M$441.0K$59.0K
Growth (year over year)—+2312.3%−74.7%−4.0%−0.8%−19.4%+234.4%−89.3%−77.1%−86.6%
Gross profit$1.15M$27.2M$3.77M—$6.40M$3.91M$14.6M$640.0K——
Gross margin100.0%97.7%53.6%—95.5%72.4%81.0%33.3%——
Operating income−$16.1M$13.9M−$35.4M−$16.1M−$72.8M−$82.1M−$37.4M−$27.4M−$68.5M−$72.9M
Operating margin−1394.6%49.9%−503.4%−239.1%−1087.4%−1521.6%−207.4%−1421.6%−15535.6%−123601.7%
Net income−$16.5M$11.9M−$40.1M−$16.1M−$63.5M−$84.4M−$41.7M−$31.5M−$35.1M−$78.3M
Net margin−1428.6%42.7%−569.9%−238.1%−947.9%−1563.1%−230.8%−1639.5%−7965.8%−132642.4%
EPS (diluted)−$1.87$0.42−$1.20———−$1063.00−$113.58−$20.91−$5.84
Balance sheet
Cash and equivalents$5.13M$2.47M$10.6M$3.61M$18.9M$54.6M$13.2M$7.42M$134.5M$15.9M
Total assets$5.77M$42.8M$70.3M$36.1M$43.8M$80.2M$33.4M$21.0M$150.7M$116.5M
Total liabilities$5.56M$14.9M$49.3M$15.1M$19.2M$57.1M$44.3M$13.7M$17.7M$33.4M
Long-term debt$0$0$14.3M———————
Shareholders' equity$207.0K$27.9M$20.9M$21.0M$24.6M$23.1M−$10.9M$7.30M$133.0M$83.0M
Cash flow
Operating cash flow−$14.6M$12.6M−$3.13M−$19.1M−$40.5M−$70.9M−$26.8M−$30.7M−$49.1M−$51.5M
Capital expenditure$34.9K$23.3K$564.4K$262.0K$63.0K$113.0K$95.0K$158.0K$0—
Free cash flow−$14.6M$12.6M−$3.69M−$19.4M−$40.6M−$71.0M−$26.8M−$30.8M−$49.1M—

From Avalo Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Avalo Therapeutics in the news

Nov 20, 2026 GlobeNewswire Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Nov 10, 2026 Investing.com Avalo Therapeutics at Stifel 2026 Healthcare Conference: phase iii ahead
Nov 6, 2026 Investing.com Stifel cuts Avalo Therapeutics stock price target on trial data
Oct 26, 2026 Investing.com Oppenheimer cuts Avalo Therapeutics price target on trial concerns Target

About Avalo Therapeutics

Headquarters
Wayne, Pennsylvania From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →